Sees FY24 non-GAAP gross margin on net product sales 89%-91%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
- Regeneron Announces New CFO and Executive Promotions
- 2seventy Bio upgraded to Outperform at Leerink on acquisition potential
- REGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 2seventy Bio cut to Market Perform at TD Cowen as outlook hinges on Abecma